Anxiety and depression in oncology patients; a longitudinal study of a screening, assessment and psychosocial support intervention
Authors:
- Annika Thalén-LindströmATAnnika Thalén-Lindström
- Gunnel LarssonGLGunnel Larsson
- Bengt GlimeliusBGBengt Glimelius
- Birgitta JohanssonBJBirgitta Johansson
- 30 August 2012
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 52 (1) , 118-127
Abstract
Background. Anxiety and depression in cancer patients are associated with poor health-related quality of life (HRQOL). Clinical interventions to detect and support patients with these symptoms need to be developed and evaluated. We investigated the feasibility of screening with the Hospital Anxiety and Depression Scale (HADS) in a clinical oncology setting. In patients with anxiety or depression symptoms (HADS >7) we explored the use of clinical assessment and psychosocial support and described the development of anxiety, depression and HRQOL during a six-month period. Material and methods. Four hundred and ninety-five consecutive patients were screened for anxiety and depression at the time of their first visit at an oncology department (baseline). Half of the patients with HADS >7 on any of the two HADS subscales were referred to clinical assessment and psychosocial support (intervention group, IG) and half received standard care (SCG) using a historical control group design. HADS and EORTC QLQ-C30 were completed at baseline and after one, three and six months. Results. One hundred and seventy-six (36%) of 495 patients had anxiety or depression symptoms at screening, HRQOL at baseline was clearly impaired for them. Thirty-six (43%) of 84 IG patients attended clinical assessment, resulting in subsequent psychosocial support for 20 (24%) of them. In the SCG, only five (5%) patients attended clinical assessment after self referral, two received subsequent psychosocial support. Anxiety and depression decreased and HRQOL increased statistically significantly over time although anxiety was frequent and HRQOL impaired during the entire six month period. There were no differences between the SCG and IG regarding anxiety, depression or HRQOL at any time point. Conclusion. Systematic screening with HADS is feasible for oncology patients in clinical settings; it identifies patients with persistent symptoms and increases referral to clinical assessment and utilisation of psychosocial support.Keywords
This publication has 33 references indexed in Scilit:
- Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trialsThe Lancet Oncology, 2009
- Major depression after breast cancer: a review of epidemiology and treatmentGeneral Hospital Psychiatry, 2008
- Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom studyBritish Journal of Cancer, 2007
- Rehabilitation of cancer patients – research perspectivesActa Oncologica, 2007
- Screening new cancer patients for psychological distress using the hospital anxiety and depression scalePsycho-Oncology, 2006
- Anxiety Disorders in Cancer Patients: Their Nature, Associations, and Relation to Quality of LifeJournal of Clinical Oncology, 2002
- The validity of the Hospital Anxiety and Depression ScaleJournal of Psychosomatic Research, 2002
- Psychiatric morbidity and its recognition by doctors in patients with cancerBritish Journal of Cancer, 2001
- The prevalence of psychological distress by cancer sitePsycho-Oncology, 2001
- How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?British Journal of Cancer, 2001